Reading the tape
NASDAQ: SILO
Silo Pharma, Inc.
Healthcare · Biotechnology
Market Cap
$3.69M
52w High
$1.13
52w Low
$0.22
P/E
-1.45
Volume
345.03K
Outstanding Shares
8.01M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -37.85%Revenue (TTM): 0%FCF (TTM): -21.58%P/S: 79th pct
What changed
The stock fell 37.85% over the last year. Revenue was flat over the trailing twelve months. Operating margin moved from -6,615.07% to -5,936.95%. Free cash flow declined 21.58% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -5,936.95%. A decisive move in revenue — currently down 0% — would be the clearest signal to resolve the ambiguity.
Company profile
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company.
CEOEric Weisblum
SectorHealthcare
IndustryBiotechnology
Employees3
IPO dateJan 8, 2021
Valuation
Forward P/E—
EV/EBITDA0.44
Enterprise value-$1.9M
Stock splits
Sep 15, 2022↓ Reverse
Every 50 shares became 1
Profitability & growth
Revenue growth0%
Gross margin-602.78%▼1328.35%vs FY2024
Operating margin-5,936.95%▲9.03%vs FY2024
ROE-67.05%▲23.16%vs FY2024
Analyst consensus
Rating—
Target price—
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 8, 2026
Q2 FY26 · EPS est -$0.32 · Revenue est $18K
View